Witryna28 mar 2024 · IMpower132是一项全球多中心、开放标签、随机对照的Ⅲ期临床试验,旨在探索阿替利珠单抗联合培美曲塞+铂类(卡铂/顺铂,APP组),对比培美曲塞+铂类(PP组)一线治疗EGFR/ALK阴性、未经化疗的晚期非鳞NSCLC的疗效和安全性。 IMpower132研究设计 在2024年欧洲肿瘤内科学会亚洲年会(ESMO Asia) … Witryna16 wrz 2024 · In IMpower133, investigators assessed the safety and efficacy of the addition of atezolizumab, an inhibitor of PD-L1, versus placebo to first-line carboplatin and etoposide in four 21-day cycles, followed by a maintenance of atezolizumab versus placebo based on the initial randomization, in a 1:1 double-blind randomization of 403 …
ESMO Asia: ASTRUM-005研究再次刷新广泛期小细胞肺癌生存高 …
Witryna23 lip 2024 · The IMpower133 study shows that atezolizumab plus chemotherapy significantly prolonged overall survival (OS) (HR: 0.76; 95% CI: 0.60 to 0.95) and progression-free survival (PFS) (HR: 0.77; 0.63 to 0.95) compared to … WitrynaIMpower133 efficacy results in 1L ES-SCLC Quick Links Primary OS analysis Updated exploratory OS analysis Additional Phase III clinical data Primary OS analysis The … how to stop drinking pepsi
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients …
Witryna另外,两项III期研究显示PD-L1抑制剂联合化疗一线治疗广泛期SCLC(extensive-stage small cell lung cancer, ES-SCLC)的疗效优于单纯化疗:在IMpower133研究中,阿替利珠单抗联合化疗的总生存期(overall survival, OS)为12.3个月,死亡风险较单纯化疗减少30%[12];在CASPIAN研究中 ... Witryna31 sty 2024 · January 31, 2024 - The latest data from the IMpower133 trial shows that maintenance therapy with atezolizumab plus carboplatin and etoposide improves overall survival and progression-free... Witryna13 paź 2024 · 2024年世界肺癌大会(wclc),五款抗肺癌新药,肺癌最新药物震撼登场世界肺癌大会(wclc)是世界上最大的致力于肺癌和其他胸部恶性肿瘤的多学科肿瘤学会议,每届都有来自全球100多个国家的7,000多名专业人士参会,共同探讨肺癌和其他胸部恶性肿瘤的最前沿治疗进展。 how to stop driving